Date Filed | Type | Description |
10/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
10/10/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/17/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
07/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/30/2023 |
SC 13D/A
| HHLR ADVISORS, LTD. reports a 8.3% stake in I-MAB |
05/26/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/01/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/01/2023 |
6-K
| Quarterly results |
05/01/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
04/25/2023 |
6-K
| Quarterly results |
04/25/2023 |
6-K
| Quarterly results |
04/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
03/31/2023 |
6-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 0% stake in I-MAB-SPONSORED ADR |
02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/07/2023 |
SC 13G/A
| GIC Private Ltd reports a 6.3% stake in I-MAB |
11/10/2022 |
6-K
| Quarterly results |
09/30/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/13/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022",
"I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome GAITHERSBURG, MD. and SHANGHAI, China – September 13, 2022 – I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 meeting with the Center for Drug Evaluation of China’ s National Medical Products Administration , and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab, a novel CD47 antibody, in combination with azacitidine for the first-line treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome . The..." |
|
08/30/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/16/2022 |
6-K
| Quarterly results |
06/17/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
06/13/2022 |
SC 13G
| Infini Master Fund reports a 6.1% stake in I-MAB |
05/27/2022 |
6-K
| Quarterly results |
05/18/2022 |
6-K
| Quarterly results |
05/05/2022 |
6-K
| Quarterly results |
04/29/2022 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
04/28/2022 |
6-K/A
| Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] |
04/28/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
|